Category Archives: Alternative Medicine

- Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs -

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced the first patient has been treated in the Expanded Access Program (EAP) in the United States for pegunigalsidase alfa, currently in development for the treatment of Fabry disease. Treatment was initiated on December 21, 2020 by Ozlem Goker-Alpan, M.D., founder and Chief Executive Officer of the Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) in Fairfax, Va, and Lauren Noll, Clinical Research Coordinator.

The initiation of treatment in the first patient enrolled in our EAP is an important milestone for the Fabry disease community and another reflection of our commitment to supporting patients, caregivers and their healthcare providers as they make important decisions about their health and disease management, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. Through this EAP, many patients can have access to treatment with pegunigalsidase alfa as we continue to work diligently to advance this therapy through the final stages of the regulatory review process in the months ahead. We would like to thank the Fabry patient and medical community for the support they have provided to us in the setup of this program.

The EAP is open to patients with a clinical diagnosis of Fabry disease who, in the opinion of the treating physician, have no comparable or satisfactory alternative treatment options with currently available FDA-approved therapies for Fabry disease. Other eligibility criteria apply. Patients participating in the EAP receive infusions of pegunigalsidase alfa every two weeks at 1mg/kg body weight. Information related to adverse events and other limited data will be collected from participants.

We are focused on providing patients with the widest possible range of options for high quality care, said Dr. Goker-Alpan. This is an exciting time for the Fabry disease community. We are pleased to participate in this EAP and will continue to support all efforts to help more patients have access to the treatments they need.

Pegunigalsidase alfa is an investigational product and currently not approved by the U.S. Food and Drug Administration (FDA). The effectiveness and safety of pegunigalsidase alfa have not been reviewed or approved by the FDA. Before FDA review and approval, no conclusions can be drawn on pegunigalsidase alfas efficacy and safety profile. When seeking expanded access, treating physicians should consider all possible risks of treatment with pegunigalsidase alfa. Access must be compliant with all applicable federal and state laws and regulations. Investigators should not seek reimbursement for product provided to patients who participate in a government-funded insurance program.

In November 2020, the FDA extended the Prescription Drug User Fee Act (PDUFA) date to April 27, 2021 for review of the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease. Concurrently with the EAP, pegunigalsidase alfa is being evaluated in patients with Fabry disease under an open Investigational New Drug application in the Phase III BALANCE, BRIGHT and BRIDGE clinical trials and other related open label studies.

The Expanded Access Program is listed on ClinicalTrials.gov Identifier: NCT04552691 (https://clinicaltrials.gov/ct2/show/NCT04552691). Additional information on Chiesis Expanded Access policy is available at https://www.chiesiusa.com/sustainability/expanded-access-programs/. Treating physicians must submit requests on behalf of their patients for consideration via the EAP request portal at https://chiesi.versaic.com.

About Fabry Disease

Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal GalactosidaseA enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb3) in blood vessel walls throughout a person's body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the GalactosidaseA enzyme, which is normally responsible for the breakdown of Gb3. The abnormal storage of Gb3 increases with time and, accordingly, Gb3 accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb3 deposition range from episodes of pain and impaired peripheral sensation to end-organ failure particularly of the kidneys, but also of the heart and the cerebrovascular system.

About Pegunigalsidase Alfa

Pegunigalsidase alfa is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant -Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties.

About Chiesi Global Rare Diseases

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit http://www.chiesiglobalrarediseases.com.

About Chiesi Group

Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and is integrated with R&D groups in France, the USA, the UK, and Sweden to advance Chiesi's pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people. Chiesi Group is a certified Benefit corporation. For more information, please visitwww.chiesi.com.

Chiesi Group Media ContactValentina BiaginiSenior Group Communication Manager Chiesi Groupv.biagini@chiesi.com

Chiesi USA Media ContactJenna UrbanBERRY & COMPANY PUBLIC RELATIONS, LLCT: 212 253-8881jurban@berrypr.com

PP-EF-0063 V1.0

PDF available:http://ml.globenewswire.com/Resource/Download/efd466cf-658c-4f9e-b113-e976dbace967

Read more here:

Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry...

After months of expedited clinical trials, several coronavirus disease 2019 (COVID-19) vaccines are now nearing market distribution, and a few are already out for public use.

One of these is Pfizer Inc. and BioNTech SEs messenger RNA-based vaccine which was used in the mass immunization campaign of the United Kingdomthe first country to vaccinate its citizens.

On Dec. 8, 90-year-old Margaret Keenan made history as the first to receive the vaccine.

In the Philippines, at least four pharmaceutical companies are currently undergoing evaluation for independent clinical trials, minus AstraZeneca which recently withdrew its application according to news reports saying they already have enough data. (SEE VERA FILES FACT SHEET: Getting to know the COVID-19 vaccine prospects in the Philippines)

Meanwhile, at least 17 other vaccine candidates are being considered for procurement as of Nov. 27 according to Jaime Montoya, executive director of the Department of Science and Technology Philippine Council for Health Research and Development.

But to get vaccinated, one has to deal with another COVID-19 related epidemic.

Apart from the obvious health threats the COVID-19 pandemic has brought, the outbreak was also accompanied by a global infodemic, which the World Health Organization (WHO) described as an overabundance of information, both online and offline, accurate and false.

As the first pandemic in the social media era, the stakes are higher. The same technology which helps enlighten the public is also responsible for the proliferation of misinformation.

The WHO said mis- and disinformation can be harmful to peoples physical and mental health; increase stigmatization; threaten precious health gains; and lead to poor observance of public health measures.

In fact, International Federation of Red Cross and Red Crescent Societies President Francesco Rocca identified misinformation as a parallel pandemic of mistrust in a Nov. 30 press release.

The WHO also likened the spread of misinformation to the way a virus is transmitted.

One person might share fake news with their friends and family, and then a handful of them share it with more of their friends and family, and before you know it, potentially harmful or dangerous information is taking over everyones newsfeed, it said in its information sheet on navigating misinformation and disinformation.

By implanting fear through misinformation, vaccine participation may be affected. Immunization campaigns for the promotion of safe and effective vaccines may not reach their targets, continuing the survival of the virus, according to a Sept. 23 joint statement by the WHO and other global partners.

To help flatten the infodemic curve, VERA Files spoke to Nat Gyenes from global nonprofit Meedan, who writes and researches about the intersection of health and technology and is a guest lecturer on health at the Harvard School of Public Health. She said these are the red flags to look out for in COVID-19 vaccine misinformation.

Furthermore, if it is a true claim, it should also be a massive, breaking news event! added Gyenes.

Avoid posts or content which promote conspiracy theories and falsely debunk evidence-based scientific research. Many of those who dive into vaccine conspiratorial thinking are vaccine deniers - these refer to individuals who have a very negative attitude towards vaccination and not open to a change of mind no matter what the scientific evidence says, according to the WHO.

They may choose to ignore, reject and twist the scientific consensus or be selective about the information.

Vaccine-safety knowledge may be influenced by culture and beliefs, but each country has specific credible government- and expert-backed sources of information. Local government units may help locals better understand considering the familiarity of the living environment.

Lack of knowledge about the vaccines adverse effects may increase health risks, which could lead to a degradation of trust and confidence in health experts, immunization campaigns and governments.

Close relatives of people who will receive a vaccine also deserve to know the details about the vaccine, such as its name, expected or potential adverse effects, and health-related response in the occurrence of a side effect.

There are cases of safety and efficacy concerns for traditional medicine, said Gyenes, citing health experts from Meedan's Digital Health Lab who claim there is currently no scientific evidence to support using home or traditional therapies to prevent COVID-19.

In cases where individuals may prioritize alternative medicine above science-based conventional medical care, it can cause harm by, for example, contributing to delayed adherence to effective treatments, or putting individuals at unnecessary risk, she added.

Vaccine roll-out is an important global priority. And in 2021, more COVID-19 vaccines will be ready for public use. But not everyone trusts these health organizations and even governments that promote vaccines.

It is important for the global public health community to acknowledge that there is legitimate mistrust that communities experience in health institutions, said Gyenes.

To remedy the situation, Gyenes suggests more accessible content in a variety of languages, with localized health information available across health and information literacy levels.

Use of the native tongue in disseminating information helps skeptics rebuild their confidence in public health experts and institutions.

Sources

BBC News, Covid-19 vaccine: First person receives Pfizer jab in UK, Dec. 9, 2020

CNN, First Britons receive Covid-19 vaccine, a landmark moment in the pandemic, Dec. 8, 2020

The Manila Times, Vaccine developer drops PH trials, Dec. 13, 2020

The New York Times, Coronavirus Vaccine Tracker

NPR, U.K. Begins Nationwide Coronavirus Immunization, Largest In Nation's History, Dec. 8, 2020

Philstar.net, AstraZeneca backs out of planned vaccine trials in the Philippines, Dec. 11, 2020

Rappler, AstraZeneca no longer conducting COVID-19 vaccine trials in Philippines, Dec. 11, 2020

World Health Organization, Managing the COVID-19 infodemic: Promoting healthy behaviours and mitigating the harm from misinformation and disinformation, Sept. 23, 2020

World Health Organization, MODULE 6 Communication

World Health Organization, Responsible media reporting on COVID-19 vaccines, Dec. 7, 2020

World Health Organization Regional Office for Europe, Best practice guidance: How to respond to vocal vaccine deniers in public

World Health Organization Regional Office for Europe, EFFECTIVE COMMUNICATION OF IMMUNIZATION DATA

Read the original:

YEARENDER: Five red flags to look out for in COVID-19 vaccine misinformation - Vera Files - Vera Files

SINGAPORE - Patients with lower back and neck pain are now eligible for subsidised acupuncture treatment at public sector specialist outpatient clinics.

This pilot programme will provide referred patients with means-tested subsidies that can cover up to 70 per cent of treatment costs, announced the Ministry of Health (MOH) on Tuesday (Dec 29).

About 2,000 patients per year, or 70 per cent of all who visit public specialist outpatient clinics for pain in the lower back and neck area, are set to benefit under this pilot.

Merdeka Generation and Pioneer Generation seniors will enjoy an additional 25 per cent and 50 per cent off the remaining healthcare bill respectively.

All patients, regardless of their subsidy status, will also be able to pay for acupuncture services to relieve lower back and neck pain using their Flexi-MediSave scheme.

The scheme, introduced by the Health Ministry in 2015, aimed to reduce out-of-pocket costs for older Singaporeans at polyclinics, general practitioner clinics on the Community Health Assist Scheme (Chas), and public specialist outpatient clinics.

Seniors can begin to benefit from the Flexi-MediSave scheme once they are 60 years of age.

Those who qualify can withdraw up to $200 per year from their own MediSave account or that of their spouse to pay for outpatient treatments.

"The pilot will not cover acupuncture used to treat other pain indications, and other forms of traditional, complementary and alternative medicine currently offered at public healthcare institutions," said MOH.

See more here:

Patients with lower back, neck pain to get subsidised acupuncture treatment under pilot programme - The Straits Times

The Department of Thai Traditional and Alternative Medicine is pushing for the use of medical cannabis in traditional Thai medicines, with plans to cultivate the cannabis plant at 150 Tambon Health Promoting Hospitals nationwide.

Director-General of the Department of Thai Traditional and Alternative Medicine, Amporn Benjaponpitak, has declared the department's use of cannabis with Thai traditional medicine in the 2020 fiscal year a success.

Dr Amporn said the Public Health Ministry had included medical cannabis in its service plan for the 2020 fiscal year.

This was in line with the government's policy to make further use of local wisdom and knowledge to develop innovative processed agricultural products.

It is also the government's policy to promote research and development on medical cannabis to add economic value to the plant, said Dr Amporn.

For the 2021 fiscal year, the department will focus on developing quality cannabis farms to generate income for people and ensuring there is a sufficient supply of medication made with medical cannabis in the national healthcare scheme.

According to the department's chief, the department has piloted a project to cultivate cannabis at Tambon Health Promotion Hospitals in collaboration with community enterprises.

In the project's first phase, medical cannabis will be cultivated for the production of traditional Thai medicine. Three hospitals have already cultivated cannabis plants.

The second phase is aimed at increasing the number of medical cannabis farms to 150 nationwide.

Presently, 54 hospitals in 20 provinces and 11 health areas have received a licence to cultivate cannabis from the narcotic drugs committee.

In the third phase, medical cannabis will be used to treat palliative care patients. The goal of this phase is to promote the cultivation of medical cannabis by community enterprises.

Dr Amporn added that the department's medical cannabis plan for the 2021 fiscal year had the objective of developing legal cannabis farms for the production of traditional Thai medicine, educating people about legal medical cannabis and increasing health options for people.

Meanwhile, Justice Minister Somsak Thepsutin disclosed that the draft of the Kratom (Mitragyna speciosa) Act is in its second reading stage by a committee chaired by himself.

The Kratom Act draft is expected to be reviewed by parliament in early 2021.

Read the original post:

Dept pushing for cannabis use in Thai traditional medicines - Bangkok Post

Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphinel

CHESTERBROOK, Pa., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at ANESTHESIOLOGY 2020, the national conference for the American Society of Anesthesiologists (ASA). The conference was held virtually from October 2nd to 7th, 2020. The presentations included three posters, all of which discussed new analyses of data from the OLINVYK Phase 3 program.

Throughout its clinical development, OLINVYK has demonstrated a consistently favorable side effect profile, said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc. I am pleased that we are still gaining valuable clinical insights into its differentiated profile as we continue to examine the robust Phase 3 data, which is clearly of great interest to clinicians looking for alternative treatment options for the treatment of acute pain.

Poster Details

1. (Poster #A4280) Evaluating Predictive Value Of Postoperative O2 Saturation Levels To Rate Of Respiratory Safety Events In Oliceridine Trials, with lead author Sabry Ayad, M.D., Department of Anesthesiology at Cleveland Clinic.

2. (Poster #A4281) Improved Tolerability With Oliceridine Compared To Morphine At Equianalgesic Doses, with lead author Gregory Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University.

A secondary analysis was conducted on the data from the OLINVYK Phase 3 pivotal RCTs in order to evaluate the safety of OLINVYK, compared to IV morphine, when adjusted for equal levels of analgesia. A composite safety endpoint was defined using the adverse events (AEs) that occurred in 10% of patients who received either OLINVYK or IV morphine (nausea, vomiting, sedation, dizziness, pruritus, and hypoxia). The incidence of the individual AEs was also assessed.

3. (Poster #A4284) Reduced Incidence Of Postoperative Vomiting With Oliceridine Than Morphine At Equianalgesic Doses, with lead author Tim Beard, M.D., Chair of the Department of Surgery at Summit Medical Group.

A retrospective analysis was conducted on the gastrointestinal (GI) tolerability data from the OLINVYK Phase 3 RCTs, using a complete GI response endpoint. A complete GI response is defined as the proportion of patients who complete the study without vomiting and without using any anti-emetics.

All posters can be found at https://www.trevena.com/publications.

About OLINVYK (oliceridine) injection

OLINVYK is a new chemical entity approved by the FDA in August 2020. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will not be available for distribution until the United States Drug Enforcement Administration assigns it to its schedule of controlled substances. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at http://www.OLINVYK.com.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please visit http://www.Trevena.com

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Companys strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words anticipate, believe, estimate, expect, intend, may, might, plan, objective, predict, project, suggest, target, potential, will, would, could, should, continue, ongoing, or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Companys clinical trials or any future trials of any of the Companys investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Companys assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Companys intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Companys therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Companys Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Investor Contact:

Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com(617) 430-7576

Company Contact:

Bob YoderSVP and Chief Business OfficerTrevena, Inc.(610) 354-8840

See the rest here:

Trevena, Inc. Announces Three OLINVYK Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting - BioSpace

Headache may be one of the most recognizable health concerns, but managing it may not always be clear. A presentation at the virtual 2020 American Academy of Pediatrics National Conference & Exhibition offers a tiered approach to aid in management.

Its not an uncommon diagnosis. In fact, its the number 1 pediatric neurologic reasonfor going to the doctor for a visit, utilizing either urgent care or the emergency department, and for referral to pediatric neurology. The headache is also responsible for roughly 200,000 missed days of school per year in the United States. Managing headaches can require deft handlingand Christopher B Oakley, MD, assistant professor of neurology at Johns Hopkins Medicine in Baltimore, Maryland, offered an approach to follow in his presentation Heads up: Headache management in primary care at the virtual 2020 American Academy of Pediatrics National Conference & Exhibition.

Oakley offered a 4 tier approach to headache management. In the first tier, the clinician should address the lifestyle of the patient who is presenting with headache. Questions about day-to-day activities mayinclude asking whether the child is achieving adequate sleep duration, finding out how much caffeine the child is ingesting, inquiring after the level of hydration, as many children are often not getting the necessary intake of water, whether the child is getting enough physical activity in a week, and discovering how busy the child is. The second tier looks at whether complementary and alternative medicines or therapy can help treat the problem. This tier may include having the child participate in cognitive behavioral therapy, use supplements as CoQ10, or utilize physical therapy. The third tier involves prescribing prophylactic medications such as amitriptyline and topiramate and the fourth tier includes hormonal therapies and procedures such as nerve blocks.

He also addressed how the COVID-19 pandemic may have altered the incidence of headaches as well as treatment. He highlighted how the pandemic has increased stressors because of changes in family dynamics along with increased social isolation. Virtual learning also led to different experiences such as lower educational quality, lack of extracurricular activities, increased screen time, and a feeling of separationfrom peers. Oakley used the case of a 16-year-old girl to illustrate the impact. She had increased migraines since the start of the pandemic; hadnt seen her psychologist or physical therapist since before the pandemic began, did not do well with the lack of structure inherent to virtual learning, and was anxious because of familial concerns.

Read more:

Managing headache with a tiered approach - Contemporary Pediatrics

On most days of the week, whether its at school or at work, life can be quite stressful. The traffic is either terrible or there are too many assignments, whatever the reason, stress, and anxiety loom over us. Anxiety can either be chronic or happen every once in a while, but either way, it is a terrible feeling that stops us from getting through the day successfully. Many people feel anxious about the past or upcoming events and opt for medication, such as antidepressants. These have different effects on each person and they always have some sort of side effect.

Read on to learn about alternative ways to calm yourself without taking medicine.

Exercise releases endorphins, which are part of the happy chemicals that your body produces. This can make you less anxious and help you sleep much better at night. You may be energetic after working out or during your workout, but as the day passes, you will find yourself tired at night and unable to hold your phone. If you make it a point to exercise on a regular basis, this will do wonders in calming your mind and helping you stay focused as well.

For someone who has anxiety or is quickly triggered, caffeine is not good news. Given that caffeine is a stimulant, it can get you hyped up and overly energetic. Caffeine can prompt the fight or flight response which makes anxiety much worse. Instead, you can opt for decaf coffee, herbal tea, ginger tea, dandy blend, or kratom tea from a trustedwebsite if you enjoy hot drinks. Doing your research will give you the best drinks to alleviate your anxiety. Caffeine is also found in chocolate, so unless you enjoy imitation chocolate made from soy, try to limit your chocolate intake.

Anxiety can causesleeping disorders and lack of sleep can cause anxiety. This is a tedious loop that can keep you anxious and tired for weeks on end. After exercising or doing a bunch of activities, try to sleep for about 7-9 hours in order to wake up calm and ready to tackle your day. Studies show that while you sleep, your mind organizes your thoughts and allows you to think clearly. Therefore, if you are constantly worried about something, a good nights sleep will help you sort it out and find solutions for the issue.

It is rare to find a yogi who is stressed. Yoga and meditation are two of the ways that can definitely reduce stress and keep you calm. The act of yoga and meditation allows you to work on your mindfulness, which helps you think about the here and now rather than focusing on the past or future issues.

We often have so many thoughts in our heads and our mind exaggerates issues that can be fixed in no time. You can write down these thoughts and get them off your chest to feel less burdened. Also, if you happen to feel as though you have a lot to do, write down the tasks and divide them according to accessibility and find out which will be the quickest to finish. Completing any task will give you peace of mind and a sense of accomplishment.

One of the best ways to treat yourself and be calm is by going to a spa. A good hour-long massage will loosen up your muscles and help you to feel super relaxed- which will certainly help you sleep. Studies also show that the heat from the sauna can make you feel calmer, as you are focused on the here and now rather than focusing on whatever it is that is making you anxious or stressed.

As clich as this sounds, the fastest way to calm down is to take deep breaths. Those who are hyperventilating breathe in and out of a bag to help them slow down a little and get their thoughts in order. Take the time to breathe. If you are stressed about work, breathe in and out and go to your happy place. Your happy place could be a time you went to the beach, hanging out with family, or even that 5 pm on a Friday afternoon when you are done with work for the week. No matter what it is, think about it and breathe deeply in and out and you will find yourself calmer in no time.

Although medication is the easiest way out, it can be problematic. The side effects of medication on each individual differs and you never know how it might affect you. Try the tips provided here in whichever order you want, but be sure that you go through each one and give them a chance before visiting a doctor to prescribe something. The main step you should take is to determine what the stressor is and take the time to tackle it rather than try to avoid the issue altogether.

KHTS FM 98.1 and AM 1220 is Santa Claritas only local radio station. KHTS mixes in a combination of news, traffic, sports, and features along with your favorite adult contemporary hits. Santa Clarita news and features are delivered throughout the day over our airwaves, on our website and through a variety of social media platforms. Our KHTS national award-winning daily news briefs are now read daily by 34,000+ residents. A vibrant member of the Santa Clarita community, the KHTS broadcast signal reaches all of the Santa Clarita Valley and parts of the high desert communities located in the Antelope Valley. The station streams its talk shows over the web, reaching a potentially worldwide audience. Follow @KHTSRadio on Facebook, Twitter, and Instagram.

See the article here:

Alternative Ways To Calm Yourself Without Taking Medicine - KHTS Radio

This story is part of a series of profiles, The CannaInfluencers: The people shaping the cannabis industry in the Garden State. Written by NJ Cannabis Insider reporters, the profiles will publish the weeks leading up to the Nov. 3 election, when New Jersey voters will decide whether to legalize recreational, adult-use cannabis.

One of the ironies of the ruthless and litigious marijuana industry is that it bears no resemblance to the delicate cannabis plant, heralded for its pain-relieving, muscle-relaxing and calming properties.

Even in this inhospitable environment, patients, lawmakers, license holders, and even some critics agree that Jeff Brown has thrived.

While the number of cannabis companies cannot expand beyond the current nine (with a total of 12 retail locations) because of the pending lawsuits challenging the health departments choice of applicants, Brown has presided over a medicinal marijuana program that has seen tremendous growth. Registered patients have swelled from nearly 19,000 to 90,000 patients since his arrival in April 2018. As an assistant health commissioner, he has implemented changes some enacted by the governor and state Legislature, some pandemic-driven that have enabled patients to buy their medicine safely and with fewer bureaucratic hoops to clear.

His fans include the co-founder of the Coalition for Medical Marijuana-New Jersey, a patient and advocate group that has been critical of the program.

I am very grateful for Jeff Browns willingness to meet with us, the CMMNJ Board members, to listen to us, and to address many of our concerns, said Ken Wolski, who is also a nurse and a registered patient.

Jeff even reached out to me, unsolicited, on a couple of occasions for my input on issues such as THC concentration in medical products, Wolski said.

Cannabis attorney Bill Caruso said Brown keeps the patients perspective close at hand in whatever hes doing, such as his decision to expedite the registration process for terminally ill patients.

He has done a fantastic job under extraordinary statutory and regulatory hurdles and delivering for patients, Caruso said. Having the right person at the top matters.

Brown describes the job as frequently rewarding and at times incredibly frustrating.

Some days, Brown fields calls from aggrieved parties who are fighting for a piece of the medicinal cannabis market, and from the lawmakers who represent them. Other days, he and his staff are getting an earful from patients frustrated they have to drive so far and pay so much for their medicine.

Observing the national cannabis market, Brown said many states are sued by entrepreneurs who dont get picked as the licensed growers and sellers. An average of 10% of unsuccessful applicants sue, he said. Its the cost of doing business.

There are so many people that want to get into the market and that makes for very hairy politics, Brown said. It has required a lot of focus on policy and politics. In everything I am doing, I try to bring it back to the patients.

The 38-year-old Rutgers University graduate and Mercer County resident may be one of the few whose primary focus is on the 10-year-old medical marijuana law at the moment. New Jersey voters will decide on Nov. 3 whether adults 21 and older should be permitted to buy marijuana taxed and sold by state-approved cultivators.

In some states, the medical market has withered after legalization. Brown said he wont let that happen.

The current medical marijuana operators, known as alternative treatment centers in New Jersey, presumably have an advantage because they are growing cannabis legally. But Brown said the state would prevent any medical provider from entering the adult market until they can demonstrate they can set aside an adequate supply for their patients.

The industrys track record on keeping up with demand has been disappointing, Brown said.

One of the things I have learned is that we are talking about a medical product and medical market but its very much driven by the laws of economics. Sitting as a regulator, I dont make laws and I cant make private industries do things, Brown said.

There are people all over the state who need access. I would really love to see the market expand, he said.

Before joining the Murphy administration, Brown held health policy jobs that focused on impoverished people and their struggle getting medical care. In one job, with the New Jersey Health Care Quality Institute, he oversaw a project to improve the Medicaid payment system. He said it surprised him to learn 60% of registered patients qualify for reduced registration fees because they have such a limited income.

This is very much the similar group of citizens I was focused on in my previous jobs, he said.

Brown came into an office hamstrung by Gov. Chris Christie, who made it clear he resented inheriting and implementing a law he didnt support. But he found 22 employees who were enthusiastic and eager to improve, Brown said. He recalled Sue Carson, the program director who has since retired, suggested making a fairly simple information technology switch that would make the patient registry available on mobile phones. It took all of one day to complete, he said.

Shortly thereafter, people could take photos of their documents at home. People were going to public libraries to do this, he said.

Brown is doing exactly what he was hired to do, Murphy said.

After eight years of stonewalling by the previous administration, in one of my first executive actions I ordered a sweeping review of New Jerseys medicinal marijuana program and appointed Jeff Brown to head the Division of Medicinal Marijuana. Under Jeffs leadership, the program has been overhauled with a compassionate, patient-centered approach that has increased the number of qualifying conditions, removed needless barriers, and expanded dispensaries across the state, Murphy said in a statement to NJ Cannabis Insider. I cant thank Jeff and his team at the Department of Health enough for their efforts to deliver sustainable, affordable access to this life-changing medical treatment for more than 90,000 patients in New Jersey a fivefold increase from when we took office.

Brown taking a selfie with his wife, Lindsey, on a vacation in Italy.

While Brown has been busy expanding the program, he and his wife, Lindsey, a physical therapist, have expanded their family. Their oldest daughter, Madison, will turn 3 in October; Sadie was born last month. Brown said he likes to travel and is a record collector, with 50s and 60s jazz performers his favorite. But the pandemic hasnt left much time for after-hours pursuits. Health Commissioner Judy Persichilli dispatched him to oversee the opening of the field hospital in Atlantic City when the coronavirus outbreak was at its height in the spring.

Presuming the polls are correct and voters approve the constitutional amendment legalizing marijuana, insiders speculate the Murphy administration will give Brown a prominent role in the cannabis regulatory commission that will regulate both the adult and medical markets. Brown said he hasnt been approached.

For now, hes focused on launching a home delivery program and finding ways to simplify the registration and renewal process for patients.

I ground myself by remembering its not about me, its not about the industry, its about them, the patients.

Industry insiders speculate Brown will have a prominent role in the cannabis regulatory commission that will regulate both the recreational and medical marijuana markets.Phil McAuliffe For The Times Of Trenton

Our journalism needs your support. Please subscribe today to NJ.com.

Susan K. Livio may be reached at slivio@njadvancemedia.com. Follow her on Twitter @SusanKLivio.

Continue reading here:

Cannabis influencers: Hes the right person at the top delivering for N.J. patients - NJ.com

Alternative Medicines and Therapies Comprehensive Study by Type (Mud Therapy, Reiki, Oil Massage Therapy, Magnetic Therapy, Some Breathing Exercises, Meditation, Yoga, Osteopathic Manipulation), Application (Hospital , Clinic), Distribution Channel (Direct Sales, E-Sales, Distance Correspondence) Players and Region - Global Market Outlook to 2025

COVID-19 Outbreak- Alternative Medicines and Therapies Market Research Study The exploration report comprised with market data derived from primary as well as secondary research techniques. The solicitation of proposals by the governments and publicprivate companies across the world to mitigate the impact of the COVID-19 pandemic is considered to be market forces.

The aim is to get premium insights, quality data figures and information in relation to aspects such as market scope, market size, share, and segments including Types of Products and Services, Application / end use industry, SWOT Analysis and by various emerging by geographies. Some of the profiled players in standard version of this study are Weleda (Switzerland), Cipla (India), Sante Verte Lab (France), Sandoz International GmbH (Germany), Biocon Ltd (India), Dr.

Reddy's Laboratories (India), Wright Health Group Ltd. (United Kingdom), Nordic Nutraceuticals (Denmark) and Pure encapsulations, LLC (United States)

Alternative medicine and therapies refer to any health treatment not standard in Western medical practice. It is referred to as complementary medicine.

Its aims to achieve the healing effects of medicine, but which lacks biological plausibility and is untested, untestable or proven ineffective.

REQUEST to GET FREE Sample PDF of COVID-19 Outbreak-Global Alternative Medicines and Therapies Market Report NOW!

Market Drivers

Market Trend

Restraints

Opportunities

Challenges

Market Competition

This report covers the recent COVID-19 incidence and its impact on Alternative Medicines and Therapies Market.

The pandemic has widely affected the economic scenario. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

Each company profiled in the research document is studied considering various factors such as product and its application portfolios, market share, growth potential, future plans, and development activity like merger & Acquisitions, JVs, Product launch. Readers will be able to gain complete understanding and knowledge of the competitive landscape.

Most importantly, the report sheds light on important strategies that key and emerging players are taking to maintain their ranking in the Alternative Medicines and Therapies Market. The study highlights how competition will change dynamics in the coming years and why players are preparing themselves to stay ahead of the curve.

Who all can be benefitted out of this COVID-19 Outbreak-Global Alternative Medicines and Therapies Market Report?

What are the crucial aspects incorporated in the COVID-19 Outbreak-Global Alternative Medicines and Therapies Market Study?

COVID-19 Outbreak- Alternative Medicines and Therapies Market Geographical Segment North America (Canada, United States & Mexico) Europe (Germany, the United Kingdom, Belgium, Netherlands, France, Russia & Italy, Others) Asia-Pacific (Japan, South Korea, China, India & Southeast Asia) South America (Argentina, Brazil, Peru, Colombia, Etc.) Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)

Have Any Questions Regarding Alternative Medicines and Therapies Market Report, Ask Our Experts@

http://www.advancemarketanalytics.com/enquiryies-market

The titled segments and sub-section of the market are illuminated below:

Type (Mud Therapy, Reiki, Oil Massage Therapy, Magnetic Therapy, Some Breathing Exercises, Meditation, Yoga, Osteopathic Manipulation), Application (Hospital, Clinic), Distribution Channel (Direct Sales, E-Sales, Distance Correspondence)

Business StrategiesKey strategies in theCOVID-19 Outbreak-Global Alternative Medicines and Therapies Market that includes product developments, partnerships, mergers and acquisitions, etc discussed in this report. The worth of strategic analysis has been rigorously investigated in conjunction with undisputed market challenges.

Type 1 of COVID-19 Outbreak- Alternative Medicines and Therapies market is expected to the dominate the overall market during the forecast period till 2026. The market will boost by application XX to improve operations efficiently and with minimum operational cost.

Rethink to Unleash Growth Pattern due to COVID-19; Know More@ http://www.advancemarketanalytics.com/reportsies-market

Strategic Points Covered in Table of Content of Alternative Medicines and Therapies Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Alternative Medicines and Therapies market

Chapter 2: Exclusive Summary the basic information of the Alternative Medicines and Therapies Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges&Opportunities of the Alternative Medicines and Therapies

Chapter 4: Presenting the Alternative Medicines and Therapies Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2014-2019

Chapter 6: Evaluating the leading manufacturers of the Alternative Medicines and Therapies market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2020-2025)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally,Alternative Medicines and Therapies Market is a valuable source of guidance for individuals and companies.

Research Methodology:

Customization Service of the Report:-AMA Research provides customization of reports as per your need. This report can be personalized to meet your requirements.

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

(*If you have any special requirements, please let us know and we can provide ad-hoc customized report as per your requirement to meet your objectives)

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:

Alternative Medicines and Therapies Market Emerging Trends and Strong Application Scope by 2025 | Weleda, Cipla, Sante Verte Lab, Sandoz International...

The Global AYUSH and Alternative Medicine Market analysis report published on Dataintelo.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=94639

The Global AYUSH and Alternative Medicine Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global AYUSH and Alternative Medicine Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The AYUSH and Alternative Medicine Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=94639

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global AYUSH and Alternative Medicine Market as:Global AYUSH and Alternative Medicine Market Size & Share, by Regions

Global AYUSH and Alternative Medicine Market Size & Share, by ProductsAyurvedic MedicinesHerbal MedicinesAroma TherapyHomeopathyReflexologyOthers

Global AYUSH and Alternative Medicine Market Size & Share, ApplicationsWomenMenKids

Key PlayersBaidyanathHimalya HerbalsGanga PharmaceuticalsPatanjaliHamdard

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=94639

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Read the original post:

Global AYUSH and Alternative Medicine Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2026 | Baidyanath, Himalya Herbals,...